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Quinidine-Induced Immune Thrombocytopenia 
Mansoor N. Saleh, MD,* Nadhav Dhodaphar, MD,^  Karen Alien,* and 
Albert F. LoBuglio, MD§ 
We have identified six cases of quinidine-induced immune thrombocytopenia based on clinical 
evidence and in association with elevated amounts of platelet surface IgG. The degree of 
thrombocytopenia did not correlate with severity of clinical symptoms, nor did it predict the amount of 
IgG on the platelet surface. Three ofthe patients recovered promptly after drug discontinuation alone 
whereas the other patients received additional corticosteroid therapy. The clinical presentation, mode 
of diagnosis, arul therapeutic considerations in the treatment of drug-induced thrombocytopenia are 
discussed. (Henry Ford Hosp MedJ 1989:37:28-32) 
Drugs may cause thrombocytopenia by three principal mech-anisms: suppression of platelet production, direct platelet 
toxicity, or antibody-mediated platelet destmction (1). With the 
advent of assays specifically capable of detecting and quantify-
ing IgG on the platelet surface (2), it has become increasingly 
possible to recognize cases of drug-induced immune throm-
bocytopenia based on the detection of elevated levels of platelet 
surface bound IgG in association with ingestion of causative 
dmgs. Consequendy, dmg-induced immune thrombocytopenia 
is no longer a disease diagnosed primarily by exclusion. The 
occurrence of quinidine-induced thrombocytopenia, though 
uncommon, was documented as early as 1965 (3) and has 
been thought to be immune in origin (4,5). The platelets them-
selves may serve as innocent bystanders (6,7) or partial im-
munogens (8). 
We discuss six cases of clinically documented quinidine-in-
duced thrombocytopenia, outlining the mode of diagnosis as 
well as therapeutic considerations. The '^ I^-labeled monoclonal 
anti-IgG assay (2) is used for the quantitation of IgG on the 
platelet surface. We discuss the role of this assay in diagnosing 
drug-induced immune thrombocytopenia and address its 
diagnostic and prognostic value. 
Materials and Methods 
Patient population 
Subjects were retrospectively identified from the data base of 
the Immune Cytopenia Laboratory. We reviewed the charts of 
all thrombocytopenic patients seen from 1983 to 1986 whose 
blood samples had been sent for quantitation of antiplatelet anti-
bodies and who at presentation were noted to be on quinidine. 
Of a total of 450 samples assayed during that period, 28 index 
cases were identified and further reviewed. 
Selection criteria 
To identify cases of quinidine-induced thrombocytopenia, pa-
tients had to have a previously known normal platelet count and 
a documented history of quinidine ingestion. Throm-
bocytopenia should have developed during quinidine therapy 
and resolved after discontinuation of the dmg (with or without 
additional therapy). Bone marrow evaluation was required to 
document adequate marrow megakaryocytes. Patients were ex-
cluded if they had any evidence of secondary thrombocytopenia 
caused by other underlying conditions. Of the 28 index cases, 
six patients fulfilled the clinical criteria for quinidine-induced 
thrombocytopenia. The remaining 22 patients were excluded 
because of the presence of one or a combination of the following 
exclusion criteria: onset of thrombocytopenia prior to starting 
quinidine; thrombocytopenia secondary to hypersplenism, sep-
ticemia, or disseminated intravascular coagulation (DIC); or pri-
mary or chemotherapy-induced marrow hypoplastic state. 
Determination of platelet surface bound IgG 
Quantitation of IgG on the platelet surface was performed 
using the radiolabeled monoclonal anti-lgG assay previously 
described (9). Venous blood was collected in plastic syringes 
and anticoagulated with acid citrate dextrose A. The whole 
blood was centrifuged at 200 x g for 20 minutes and the 
platelet-rich plasma collected. The pH was adjusted to 6.5 with 
acid citrate dextrose A and then centrifuged at 1,750 X g for 20 
minutes. The platelet button was thrice washed in platelet-sus-
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Table 1 
Patient Characteristics 
1 2 
Patients 
3 4 5 6 
Age (years) 62 75 72 65 64 58 
Sex M F M F .M M 
Race w w W W W W 
Medical Ischemic heart Diabetes mellitus. Stage D prostatic Ischemic heart Hypertension, Ischemic heart 
history disease ischemic heari carcinoma, disease, ischemic heart disease 
disease. hypertension. arrhythmias disease 
hypertension arrhythmias 
Duration of 
quinidine 
therapy 3 months 2 years 7 days 3 months 5 months 3 years 
Additional Nitroglycerin Digoxin, insulin Isosorbide Nitroglycerin Digoxin, Phenytoin 
treatment paste. dinitrate. paste, almacone triamterene 
dipyridamole furosemide. 
digoxin 
pension buffer (Dulbecco's phosphate buffered isotonic saline 
containing 1 g/dL of bovine semm albumin and 4 mmol EDTA, 
pH 6.5). Ten million washed platelets were incubated with 300 
ng '^ I^-labeled mouse monoclonal anti-IgG in a total volume of 
300 p,L for 20 minutes at room temperature. Triplicate aliquots 
of 75 |xL (2.5 X 10* platelets) were transferred to Percoll gra-
dient tubes containing 250 p,L of isotonic 30% Percoll in saline, 
centrifuged at 7,500 x g for five minutes, and the tube tip con-
taining the platelet button was transected with a hemostat and 
razor blade into gamma counting tubes. The number of ' ^ ' I 
monoclonal antibody molecules bound per platelet was calcu-
lated based on the Avogadro number and the antibody's specific 
activity and molecular weight (9). 
Results 
The six patients who fulfilled the selection criteria repre-
sented clear-cut cases of quinidine-induced thrombocytopenia. 
All patients (four males and two females, ranging in age from 58 
to 75 years) suffered from ischemic heart disease associated 
with various arrhythmias and took quinidine in dosages ranging 
from 200 mg three times daily to 648 mg every six hours (Table 
1). The duration of dmg ingestion prior to presentation was 
highly variable, ranging from seven days to as long as three 
years. The majority of patients, however, had been on quinidine 
for less than six months. In addition to quinidine, most of the 
patients were on other medications (Table 1). 
Clinical parameters at presentation are given in Table 2. All 
but one patient were symptomatic. Symptoms consisted pri-
marily of petechia and easy bruisibility. One patient was 
asymptomatic at presentation despite a platelet count of 
6,000/p.L. All six patients had a platelet count of less than 
55,000/|xL, and four had a platelet count less than 10,000/p,L at 
presentation. The severity of thrombocytopenia did not correlate 
with symptoms at presentation, and none of the patients pre-
Table 2 
Clinical Parameters at Presentation 
I 2 3 
Patients 
4 5 6 
Chief 
complaints 
Pfctechiae, 
bruisibility 
Asymptomatic Bruisibility, 
epistasis, 
gum bleed 
Petechiae, 
gum bleed, 
epistasis 
Gum bleed Bruisibility 
Platelet nadir 
(X 103/p.L) 21 6 3 1 4 4') 
Antibody level* 3,561 816 1,498 7,610 1,426 1,665 
Bone marrow 
megakaryocytes Increased Increased Increased Increased Increased Increased 
Coagulation 
profilet 
Within normal 
limits 
Within normal 
limits 
Within normal Within normal 
limits limits 
Within normal 
limits 
Within normal 
limits 
*Plitfelet surface bound IgG (moiecules IgG/plalelet). 
tFVothrombin time; partial thromboplastin time. 
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Table 3 
Clinical Course 
1 2 3 
Patients 
4 5 6 
Platelet count at admission ( x IO^/IJLL) 21 6 3 6 4 53 
Time point of drug discontinuation DayO DayO DayO DayO DayO DayO 
Response to drug discontinuation alone Yes Yes Yes No No No 
Additional therapy (day started) None None None Prednisone Prednisone Prednisone 
(day 4) (day 3) (day 5) 
Duration of additional therapy 
— — — 
4 days 7 days then 3 days 
tapered 
over 
8 weeks 
Time point of response 
(platelet count > 100,000 JJLL) Day 5 Day 11 Day 3 Day 8 Day 10 Day 8 
Postrecovery platelet counts 
(X 10V|xL) 233 233 286 209 206 154 
sented witb or suffered from major bleeding such as gastroin-
testinal, intracranial, or pulmonary hemorrhage. Peripheral 
blood smear in all patients revealed greatly decreased circulating 
platelets, whereas bone marrows consistently showed increased 
megakaryocytes. Complete coagulation profile was within nor-
mal limits in all patients, and no signs of bleeding diathesis were 
present. Platelet surface bound IgG levels were determined in all 
patients early on during their hospital course; all patients had el-
evated values, ranging from 816 molecules IgG/platelet in a pa-
tient with a platelet count of 6,000/p.L to 7,610 molecules IgG/ 
platelet in a patient with a platelet count of l,000/p,L (normal 
value < 400 molecules IgG/platelet) (2,10). Platelet surface IgG 
determination at recovery was performed in only one patient and 
revealed a value of 400 molecules IgG/platelet. 
The disease course of the six patients is summarized in Table 
3. Quinidine was discontinued in all patients on the day of ad-
mission (day 0) but other medications were continued. Three pa-
tients showed a prompt increase in platelet count and complete 
resolution of thrombocytopenia within three to 11 days (days 3, 
5, and 11, respectively) and received no additional treatment. 
The remaining three patients were started on steroid therapy be-
tween days 3 to 5 because of no apparent spontaneous improve-
ment in platelet count up to that time. None of these patients de-
veloped bleeding symptoms beyond those noted at presentation. 
Thrombocytopenia resolved in all three patients within three to 
four days of steroid initiation, and steroid treatment was discon-
tinued in two ofthese patients at that time. The remaining patient 
received full dose prednisone treatment for seven days with sub-
sequent tapering over the next eight weeks. Follow-up platelet 
counts on all six patients have remained in the normal range. 
The platelet profile of these patients is shown in the Figure. 
The mean recovery time (platelet count > 100,000/p.L) for 
the group was seven days with a range of three to 11 days. Pa-
tients who received no additional therapy showed normal 
platelet counts within a mean of 6.3 days compared to 8.6 days 
for patients who received steroid therapy. 
Discussion 
The '^ 'I-Iabeled monoclonal anti-IgG assay (2) was used to 
quantitate levels of platelet surface bound IgG in all patients to 
document the antibody-mediated nature of this disease and to 
uncover possible prognostic implications of platelet surface 
bound antibody quantitation. 
Differential diagnostic considerations in patients presenting 
with peripheral thrombocytopenia with adequate marrow mega-
karyocytes include DIC, posttransfusional purpura, septicemia, 
thrombotic thrombocytopenic purpura, and immune throm-
bocytopenic purpura (ITP), both idiopathic and dmg-induced. 
These five categories can be mled out based on clinical and labo-
ratory findings. Differentiating idiopathic immune throm-
bocytopenia from secondary dmg-induced thrombocytopenia 
rests primarily on the prompt response and persistent remission 
of the latter to dmg withdrawal with or without a short course 
of corticosteroids. 
Dmg-induced thrombocytopenia most commonly occurs in 
the elderly (11), presumably because of their greater exposure to 
such dmgs. In our patients the duration of quinidine intake was 
variable, with thrombocytopenia occurring as early as seven 
days to as late as three years after the start of therapy. These find-
ings indicate that as yet undetermined host-related factors may 
be responsible for the ultimate pathophysiology of the throm-
bocytopenic syndrome. 
Despite the severity of thrombocytopenia, none of our pa-
tients experienced life-threatening bleeding. There was no cor-
relation between symptoms at presentation and severity of 
thrombocytopenia. This finding is similar to that seen in ITP 
(12) and contrary to that seen in thrombocytopenia due to 
myelosuppressive therapy where the incidence of life-threat-
ening bleeding increases significantly as platelet counts fall 
below 20,000/p,L (13). The increased activity of marrow 
megakaryocytes and the continual production of young, hemo-
statically active platelets is a possible explanation for the lower 
incidence of life-threatening hemorrhage in immune platelet 
destruction syndromes, although the exact reason for platelet 
hyperfunction in this disease is still undefined. 
All patients had elevated platelet surface IgG levels, which 
clearly indicates the role of antibody in this platelet destmction 
process. The range of platelet surface bound IgG is similar to 
that described for patients with idiopathic immune throm-
bocytopenia and is different (higher) than that observed in non-
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immune thrombocytopenia (10). The monoclonal anti-IgG as-
say used in this study differs from assays previously used to 
quantitate platelet IgG levels in that it measures surface bound 
IgG rather than total cellular IgG and utilizes a high affinity 
monoclonal antibody in a direct binding method (2,9,10,14). We 
found no relationship between the severity of thrombocytopenia 
and the level of platelet bound IgG in our six patients, which is 
consistent with findings in ITP and divergent from previously 
published reports using different assay techniques (10,15). Our 
finding is not unexpected since a multitude of host-related 
factors as well as factors related to heterogeneity in terms of 
subclass content and surface distribution of antibody on the cell 
surface may determine the ultimate destruction rate of the 
opsonized target (16,17). 
Three of the six patients responded promptly to discontinua-
tion of quinidine with full platelet count recovery within one, 
three, and five days, respectively. The remaining three patients 
were started on prednisone therapy, although there was no 
clinical indication of worsening of any of the symptoms noted at 
presentation. These patients did not show any spontaneous in-
crement in platelet count three to five days after discontinuing 
quinidine. Whether the lack of prompt response to dmg discon-
tinuation was related to the persistence of circulating dmg levels 
due to delayed clearance/degradation in these patients is unclear. 
The presence of the offending agent appears to be a prerequisite 
for the pathogenesis of thrombocytopenia (18). All three patients 
started on prednisone therapy (1 mg/kg/day) achieved platelet 
counts of > 100,000/p,L within three to four days. Whether this 
prompt effect could have been achieved without prednisone 
therapy is speculative. Prednisone was immediately discon-
tinued in two patients and subsequently tapered over the ensuing 
eight weeks in the third patient. All three patients maintained 
normal platelet counts when off steroid therapy. In evaluating 
the overall clinical course of the patients who received pred-
nisone and those who did not, no difference existed in duration 
of thrombocytopenia, platelet count at recovery, or symptoms 
during the hospital course. Initial platelet counts as well as 
platelet surface bound IgG levels were not significantiy different 
in the two groups. 
Use of corticosteroids in the treatment of drug-induced 
thrombocytopenia remains a clinical judgment call. In the ab-
sence of readily available in vitro assays to detect quinidine-de-
pendent antibodies, the following three therapeutic altematives 
appear equally acceptable: drug withdrawal accompanied by 
corticosteroid treatment, drug withdrawal followed by cor-
ticosteroid therapy three days later if no reversal of throm-
bocytopenia is evident, and dmg withdrawal with careful obser-
vation of platelet count. Patients with dmg-induced throm-
bocytopenia respond promptly to platelet transfusion with 
adequate hemostasis (19). Thus, patients under observation can 
be readily managed with platelet support in the event of a poten-
tially life-threatening hemorrhage. In our opinion, most patients 
can be adequately managed with dmg discontinuation and close 
follow-up without institution of additional therapy. 
These six cases of quinidine-induced immune thrombocy-
topenia were identified based on clinical evidence (quinidine 
therapy, prompt response to dmg cessation with or without cor-
ticosteroids, and lack of dependence on corticosteroids for con-
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tinual remission) in association with elevated platelet surface 
IgG. Kelton et al (15) have documented the presence of antibody 
in the serum of such patients which reacts with platelets in a 
dmg-dependent fashion. Obviously, such an assay, if available, 
is useful for confirming the dmg-dependent mechanism. How-
ever, such assays are commonly not available or not available in 
fime to be helpful in individual patient care decisions. 
We feel that new onset of thrombocytopenia in the setting of 
quinidine administration (particularly if antibody is present on 
platelet surface) should allow a working diagnosis of drug-in-
duced thrombocytopenia. Treatment should be prompt dmg ces-
sation. Depending on clinical evidence, corticosteroids may be 
added but should be stopped, with subsequent monitoring of 
platelet count, once the platelet count increases. Persistent nor-
mal counts confirm the diagnosis of a dmg-dependent syndrome 
since virtually all patients with idiopathic or secondary immune 
thrombocytopenia will relapse after seven to ten days of cor-
ticosteroid treatment. This approach also limits patient exposure 
to the serious side effects of corticosteroid therapy. 
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